Ferreiro-Iglesias, Aida http://orcid.org/0000-0002-1458-7936
McKay, James D.
Brenner, Nicole http://orcid.org/0000-0002-7690-4925
Virani, Shama http://orcid.org/0000-0002-1163-432X
Lesseur, Corina http://orcid.org/0000-0001-6744-6750
Gaborieau, Valerie
Ness, Andy R.
Hung, Rayjean J. http://orcid.org/0000-0002-4486-7496
Liu, Geoffrey
Diergaarde, Brenda
Olshan, Andrew F.
Hayes, Neil http://orcid.org/0000-0001-6203-7771
Weissler, Mark C.
Schroeder, Lea
Bender, Noemi
Pawlita, Michael http://orcid.org/0000-0002-4720-8306
Thomas, Steve
Pring, Miranda
Dudding, Tom http://orcid.org/0000-0003-3756-040X
Kanterewicz, Beatriz
Ferris, Robert
Thomas, Sera
Brhane, Yonathan
Díez-Obrero, Virginia
Milojevic, Maja http://orcid.org/0000-0002-8248-8884
Smith-Byrne, Karl http://orcid.org/0000-0002-1932-7463
Mariosa, Daniela http://orcid.org/0000-0001-8181-1419
Johansson, Mattias J. http://orcid.org/0000-0002-3116-5081
Herrero, Rolando
Boccia, Stefania
Cadoni, Gabriella
Lacko, Martin http://orcid.org/0000-0003-2868-4822
Holcátová, Ivana
Ahrens, Wolfgang
Lagiou, Pagona
Lagiou, Areti
Polesel, Jerry http://orcid.org/0000-0001-9381-1520
Simonato, Lorenzo
Merletti, Franco
Healy, Claire M.
Hansen, Bo T.
Nygård, Mari
Conway, David I.
Wright, Sylvia
Macfarlane, Tatiana V.
Robinson, Max http://orcid.org/0000-0003-4491-6865
Alemany, Laia
Agudo, Antonio
Znaor, Ariana http://orcid.org/0000-0002-5849-4782
Amos, Christopher I.
Waterboer, Tim
Brennan, Paul http://orcid.org/0000-0002-0518-8714
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research (R01DE025712)
Article History
Received: 4 December 2020
Accepted: 13 September 2021
First Online: 12 October 2021
Competing interests
: R.F. has the following financial disclosures: Aduro Biotech, Inc (consulting); Astra-Zeneca/MedImmune (clinical trial, research funding); Bristol-Myers Squibb (advisory board, clinical trial, research funding); EMD Serono (advisory board); MacroGenics, Inc (advisory board); Merck (advisory board, clinical trial); Novasenta (consulting, stock, research funding); Numab Therapeutics AG (advisory board); Pfizer (advisory board); Sanofi (consultant); Tesaro (research funding) and Zymeworks, Inc (consultant). Where authors are identified as personnel of the International Agency for Research on Cancer/World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of the International Agency for Research on Cancer/World Health Organization. All other authors have no conflicts to disclose.